Differences

This shows you the differences between two versions of the page.

--- home:mp:olmesartan:response [01.03.2012] – external edit 127.0.0.1
+++ home:mp:olmesartan:response [08.23.2017] – [Increase in immunopathology] sallieq
@@ Line 16: / Line 16: @@
 Once the body's mechanisms for regulating hormones has adjusted to regular doses of olmesartan, patients may find that they experience immunopathology or an increase in symptoms of disease. It is often the case that this is due to olmesartan's molecular actions. In its role as Vitamin D Receptor agonist, olmesartan activates the innate immune response, which leads to the transcription of anti-microbial peptides, the body's broad-spectrum antibacterials. This results in bacterial die-off and an unpleasant increase in symptoms.
-Though the immunopathological reaction to olmesartan is near universal in the MP cohort, nothing that would suggest an increase in symptoms is listed in the [[http://medicaidprovider.hhs.mt.gov/pdf/benicar.pdf|monograph for olmesartan]]. In fact, the only adverse event in which olmesartan had a higher incidence than a placebo is for dizziness (3% vs. 1%). However, it should be noted, the patients in these studies were given Benicar only once a day.
+Though the immunopathological reaction to olmesartan is near universal in the MP cohort, nothing that would suggest an increase in symptoms is listed in the [[https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021286s020lbl.pdf|monograph for olmesartan]]. In fact, the only adverse event in which olmesartan had a higher incidence than a placebo is for dizziness (3% vs. 1%). However, it should be noted, the patients in these studies were given Benicar only once a day.
 This discrepancy underscores how crucial regular dosing of olmesartan is for achieving an immune response.

home/mp/olmesartan/response.txt · Last modified: 09.14.2022 by 127.0.0.1